The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy

Conclusion: Rituximab induced remission in all patients with corticosteroid-dependent or -resistant minimal-change glomerulopathy, and may hold great therapeutic potential with good efficacy and minimal toxicity. Mounting evidence implies that a well-conducted randomized controlled clinical trial using rituximab in adults with minimal-change glomerulopathy in both corticosteroid-resistant and corticosteroid-dependent patients is warranted.Am J Nephrol 2017;45:365-372
Source: American Journal of Nephrology - Category: Neurology Source Type: research